BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24837412)

  • 1. Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada.
    Marchand-Austin A; Memari N; Patel SN; Tang P; Deeks SL; Jamieson FB; Crowcroft NS; Farrell DJ
    Int J Antimicrob Agents; 2014 Jul; 44(1):82-4. PubMed ID: 24837412
    [No Abstract]   [Full Text] [Related]  

  • 2. Where macrolide resistance is prevalent.
    Li Y; Liu X; Zhang B; He Q; Wang Z
    APMIS; 2015 Apr; 123(4):361-3. PubMed ID: 25703275
    [No Abstract]   [Full Text] [Related]  

  • 3. [Epidemiological surveillance of Bordetella pertussis and parapertussis sensitivity to antibiotics].
    Janovská D; Výmola F
    Cesk Epidemiol Mikrobiol Imunol; 1971 Jul; 20(4):184-8. PubMed ID: 4328643
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington.
    Galanakis E; Englund JA; Abe P; Qin X
    Int J Antimicrob Agents; 2007 May; 29(5):609-11. PubMed ID: 17344029
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient.
    Yao SM; Liaw GJ; Chen YY; Yen MH; Chen YH; Mu JJ; Chiang CS
    J Med Microbiol; 2008 Dec; 57(Pt 12):1577-1580. PubMed ID: 19018032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of macrolides against Bordetella pertussis strains isolated in 1968 and 30 years later in Poland.
    Chodorowska M; Tyski S; Kuklińska D
    Clin Microbiol Infect; 2000 Jan; 6(1):50-2. PubMed ID: 11168039
    [No Abstract]   [Full Text] [Related]  

  • 7. Variation in Bordetella pertussis Susceptibility to Erythromycin and Virulence-Related Genotype Changes in China (1970-2014).
    Yang Y; Yao K; Ma X; Shi W; Yuan L; Yang Y
    PLoS One; 2015; 10(9):e0138941. PubMed ID: 26406905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis.
    Lewis K; Saubolle MA; Tenover FC; Rudinsky MF; Barbour SD; Cherry JD
    Pediatr Infect Dis J; 1995 May; 14(5):388-91. PubMed ID: 7638015
    [No Abstract]   [Full Text] [Related]  

  • 9. Shattering a myth - Whooping cough susceptible to antibiotics.
    Syed MA; Jamil B; Bokhari H
    Pak J Pharm Sci; 2016 May; 29(3):985-90. PubMed ID: 27166543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial Susceptibility and Molecular Detection of Pertactin-producing and Pertactin-Deficient Bordetella pertussis.
    Souder E; Vodzak J; Evangelista AT; Long SS
    Pediatr Infect Dis J; 2017 Jan; 36(1):119-121. PubMed ID: 27956730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The First Report of Macrolide-Resistant Bordetella pertussis Isolation in Japan.
    Yamaguchi T; Kawasaki Y; Katsukawa C; Kawahara R; Kawatsu K
    Jpn J Infect Dis; 2020 Sep; 73(5):361-362. PubMed ID: 32350216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.
    Lönnqvist E; Barkoff AM; Mertsola J; He Q
    J Glob Antimicrob Resist; 2018 Sep; 14():12-16. PubMed ID: 29486357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial therapy in whooping cough.
    Henry RL; Dorman DC; Skinner JA; Mellis CM
    Med J Aust; 1981 Jul; 2(1):27-8. PubMed ID: 6268953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program.
    Gordon KA; Fusco J; Biedenbach DJ; Pfaller MA; Jones RN
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3599-600. PubMed ID: 11709347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance.
    Wilson KE; Cassiday PK; Popovic T; Sanden GN
    J Clin Microbiol; 2002 Aug; 40(8):2942-4. PubMed ID: 12149356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
    Cimolai N
    Int J Antimicrob Agents; 2021 Mar; 57(3):106258. PubMed ID: 33310116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of antibiotic sensitivity and resistance genes of Bordetella pertussis in Chinese children.
    Lin X; Zou J; Yao K; Li L; Zhong L
    Medicine (Baltimore); 2021 Jan; 100(2):e24090. PubMed ID: 33466172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibility testing and molecular epidemiology of clinical strains of Bordetella pertussis isolated in Japan from 2001 to 2002].
    Ohtsuka M; Kikuchi K; Okada K; Higashide M; Shundo K; Sunakawa K
    Kansenshogaku Zasshi; 2004 May; 78(5):420-7. PubMed ID: 15211864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Prevalence of Macrolide-Resistant Bordetella pertussis and ptxP1 Genotype, Mainland China, 2014-2016.
    Li L; Deng J; Ma X; Zhou K; Meng Q; Yuan L; Shi W; Wang Q; Li Y; Yao K
    Emerg Infect Dis; 2019 Dec; 25(12):2205-2214. PubMed ID: 31742507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-infection with two different strains of Bordetella pertussis in an infant.
    Cassiday PK; Tobin-D'Angelo M; Watson JR; Wu KH; Park MM; Sanden GN
    J Med Microbiol; 2008 Mar; 57(Pt 3):388-391. PubMed ID: 18287306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.